Compare SPDR Gold Trust (GLD) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Medpace Holdings Inc — how do they compare? SPDR Gold Trust trades at $384.07 (market cap $139.66B), while Medpace Holdings Inc trades at $616.5 (market cap $16.82B). The key difference: SPDR Gold Trust is far larger — about 8.3× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Medpace Holdings Inc for 14 Days on average.
| GLD | MEDP | |
|---|---|---|
Market Cap | $139.66B | $16.82B |
Volume | 9,544,773 | 223,093 |
52-Week High | $495.90 | $630.19 |
52-Week Low | $362.32 | $393.42 |
Typical Hold Time | 74 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, is trading at $384.45 with a 2.28% daily gain, though technical indicators signal bearish momentum with 17 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and a strong U.S. dollar, as highlighted in recent financial news. Key support levels are at $373-$377, while resistance sits at $380-$384. Recent market sentiment remains cautious amid Federal Reserve policy uncertainty and inflation concerns.
The outlook for GLD is mixed, with near-term headwinds from monetary policy and currency strength potentially limiting upside. However, gold's role as a hedge against inflation and global debt concerns offers long-term diversification benefits. Risks include further rate hikes and dollar appreciation, but tactical buying opportunities may emerge if support levels hold.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
